Kazia Therapeutics Ltd - Company Profile

Powered by

All the data and insights you need on Kazia Therapeutics Ltd in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Kazia Therapeutics Ltd Strategy Report

  • Understand Kazia Therapeutics Ltd position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Kazia Therapeutics Ltd: Overview

Select Item

Kazia Therapeutics Ltd (Kazia) is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. The company’s product pipeline includes paxalisib (formerly GDC-0084), Cantrixil (TRX-E-002-1) and EVT801. Paxalisib is an inhibitor of PI3K /AKT /mTOR pathway to treat glioblastoma multiforme It is in phase II clinical trials. TRX-E-002-1 (Cantrixil) is a third generation benzopyran molecule that acts against cancer stem cells. Cantrixil is in phase I clinical trials for the treatment of ovarian cancer. EVT801 is a substance that blocks a cellular receptor called VEGFR3, which is responsible for the development of new blood and lymphatic vessels. The company has collaborations with various research institutes, hospitals, and universities including St Jude Children's Hospital, University of Newcastle, Dana Farber Cancer Institute and Memorial Sloan Kettering Cancer Centre to develop its pipeline. Kazia is headquartered in Sydney, New South Wales, Australia.

 Gain a 360-degree view of Kazia Therapeutics Ltd and make more informed decisions for your business Gain a 360-degree view of Kazia Therapeutics Ltd and make more informed decisions for your business Find out more
Headquarters Australia
Address Three International Towers Level 24, , 300 Barangaroo Avenue, Sydney, New South Wales, 2000
Website www.kaziatherapeutics.com
Telephone 61 2 94724100
No of Employees 12
Industry Pharmaceuticals and Healthcare
Revenue (2023) $15,600
   
   
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Kazia Therapeutics Ltd premium industry data and analytics

60+

Catalyst Calendar

Proactively evaluate Kazia Therapeutics Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Kazia Therapeutics Ltd’s relevant decision makers and contact details.

30+

Clinical Trials

Determine Kazia Therapeutics Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Pipeline Drugs

Identify which of Kazia Therapeutics Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

3

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Investigators

Review investigator profiles and find information on trial contacts across Kazia Therapeutics Ltd, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

Products and Services

Products
Product Pipeline:
Paxalisib (GDC-0084):
Glioblastoma Multiforme
XYZ
XYZ
XYZ
Understand Kazia Therapeutics Ltd portfolio and identify potential areas for collaboration Understand Kazia Therapeutics Ltd portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Kazia Therapeutics Ltd Amgen Inc Biogen Inc Gilead Sciences Ltd Prescient Therapeutics Ltd
Headquarters Australia United States of America United States of America United Kingdom Australia
City Sydney Thousand Oaks Cambridge London South Melbourne
State/Province New South Wales California Massachusetts England Victoria
No. of Employees 12 26,700 7,570 184 3
Entity Type Private Public Public Private Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
John Friend, MD Managing Director; Chief Executive Officer; Chairman - Interim Executive Board 2023 -
Mr Karen Krumeich Chief Financial Officer Senior Management 2022 -
Anna Sandham Secretary Senior Management 2023 -
Steven Coffey Director Non Executive Board 2012 -
Bryce Carmine Director Non Executive Board 2016 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Kazia Therapeutics Ltd key executives to enhance your sales strategy Gain insight into Kazia Therapeutics Ltd key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward